Objective: To describe the prevalence of insomnia symptoms among women during perimenopause and to examine differences in self-reported insomnia symptoms at different stages of perimenopause over 10 years.
S
leep disorders are present in 50 to 70 million people (Institute of Medicine, 2006) , and insomnia is the most prevalent sleep disorder among the general population (Schutte-Rodin et al., 2008) . Although insomnia is a distinctly defined sleep disorder with specific diagnostic criteria, insomnia symptoms are often examined in isolation. It is important to recognize insomnia symptoms in women during perimenopause through health care screenings and patient education for an accurate diagnosis of insomnia disorder. The Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) identifies the criteria for insomnia disorder as any one symptom of prolonged sleep latency, increased wake after sleep onset, and/or the occurrence of early morning awakenings, that is present for three or more nights per week, for three or more consecutive months, along with daytime impairment and sufficient opportunity for sleep (American Psychiatric Association, 2013) .
Within the next decade, it is projected that 500 million women in the United States will be within the estimated age range (35-55 years) to transition to perimenopause (U.S. Census Bureau, 2010) . During perimenopause, women begin to experience variations in the menstrual cycle because of the fluctuation of estradiol, progesterone, and follicle-stimulating hormones. They commonly experience symptoms that include hot flashes, night sweats, sleep disruption, and an overall decrease in quality of life (Freeman et al., 2007) . Early perimenopause is distinctly different from late perimenopause and is defined as having a menstrual cycle in the preceding 3 months but with irregularity of cycles. On the other hand, late perimenopause is defined as having a menstrual cycle in the last 12 months but not in the preceding 3 months (Harlow et al., 2012) . Chronic insomnia is a significant risk factor for new onset medical and psychiatry morbidity, and when left untreated it is costly to the individual (up to $5,000 per annum) and costly to society in the form of poor work productivity and absenteeism (up to $150 billion per annum in direct and indirect costs; Daley et al., 2009; Ozminkowski et al., 2007) . Although the evidence to date consistently indicates that insomnia symptoms and chronic insomnia diagnoses are associated with individual and societal costs and untoward general population outcomes, less is known about insomnia symptoms in women during perimenopause.
Women are at greater risk than men to develop chronic insomnia during their lifetimes (Ozminkowski et al., 2007) ; a lifetime prevalence rate of 63% was reported among women ages 18 years and older (N ¼ 511) in a U.S. study (National Sleep Foundation, 2015) . The prevalence of insomnia symptoms increases in women as they enter perimenopause (Ensrud et al., 2011; Freeman et al., 2007) , and nearly 40% of women between the ages of 40 and 55 years reported insomnia symptoms (Kravitz et al., 2003) . According to the 2007 Sleep in America Poll, 59% of women with perimenopause reported that they experienced insomnia symptoms at least a few nights per week (National Sleep Foundation, 2015) , and women who experienced other symptoms of perimenopause, such as hot flashes and depression, were more likely to also report insomnia symptoms (Arakane et al., 2011; Blü mel et al., 2012; Piene et al., 2008; Woods and Mitchell, 2010) . The alteration of hormones that occurs during the natural progression of perimenopause has the potential to increase the risk of developing insomnia because of the following factors: vasomotor symptoms that disrupt the sleep cycle, coexistent psychological disorders such as anxiety and depression that contribute to impaired sleep, and altered central neural control of sleep-wake states and thermal threshold associated with hormonal alterations (Freedman, 2005a,b) .
Untreated insomnia is a public health concern. In the general U.S. population, the cost of insomnia treatment, loss of productivity at work, and decreased quality of life confer a tremendous burden (Daley et al., 2009; Hatoum et al., 1999; Simon and VonKorff, 1997) .
Poor sleep quality in midlife women was associated with primary sleep disorders, anxiety, and depression (Joffe et al., 2010) and hypertension (Vgontzas et al., 2009) . Because the number of perimenopausal women will significantly increase during the next several decades in the United States, it is critically important to gain insight into the prevalence of diagnosable insomnia in this high-risk group. Furthermore, little is known about the prevalence of insomnia symptoms across the stages of early and late perimenopause, and such information will potentially support recommendations for the timing of insomnia screening and intervention for prevention and treatment.
The overall purpose of our study was to describe the prevalence of insomnia symptoms in perimenopausal women and to determine the prevalence of insomnia symptoms by perimenopausal stage in midlife women over a period of 10 years. The following study questions were addressed: (a) What is the prevalence of nighttime insomnia symptoms measured annually in perimenopausal women?, (b) What is the prevalence of insomnia symptoms by perimenopausal stage in women?, and (c) Is there a difference in reported insomnia symptoms by perimenopausal stage?
Methods

Design
Our study was a secondary and longitudinal analysis of publicly available data from the Study of Women's Health Across the Nation (SWAN), a multisite, longitudinal study of the natural history of women transitioning to menopause (Sowers et al., 2000) funded by the National Institutes of Health's National Institute on Aging, National Institute of Nursing Research, and Office of Research on Women's Health. The objective of the SWAN was to describe the chronology of the biological and psychological characteristics of the menopausal transition on health and risk factors for age-related chronic illnesses (Sowers et al., 2000) . The SWAN included a cross-sectional and a longitudinal component with an emphasis on the inclusion of racially/ ethnically diverse women.
Setting and Sample
For SWAN, researchers employed a random population sampling plan using telephone numbers generated from random-digit dialing lists and list-based frames such as city census, electrical utility customer lists, health maintenance organization enrollment lists, and an enrollment list from an earlier study (Sowers et al., 2000) . A total of 202,985 sampling units were screened for potential participation in the crosssectional component of SWAN, resulting in 34,446 eligible women. The study included seven sites; Boston (45% African American, 55% White), Chicago (55% African American, 45% White), Detroit (66% African American, 33% White), Los Angeles (55% Japanese, 45% White), Newark (66% Hispanic, 33% White), Oakland (55% Chinese, 45% White), and Pittsburgh (33% African American, 66% White). Of the cross-sectional participants, 6,521 women were eligible for the longitudinal component of SWAN based on the following inclusion criteria: (a) ages 42-52 years, (b) no surgical removal of the uterus and/or both ovaries before study enrollment, (c) not currently using exogenous hormone preparations affecting ovarian functions, (d) reporting at least one menstrual period in the past 3 months, and (e) self-identification with the site specific racial/ ethnic strata. A total of 3,302 women were included in the longitudinal component of the study, resulting in an overall response rate of 50.7% (Sowers et al., 2000) . Methods used in the SWAN are discussed elsewhere in more detail (Sowers et al., 2000) .
Procedure
Our secondary analysis of data from the SWAN was conducted using 10 years of publicly available data from the Inter-University Consortium for Political and Social Research. Data from perimenopause through 1 year after menopause were used to examine the differences in the insomnia symptom prevalence between perimenopausal stages. Pre-perimenopausal women were included in the baseline sample with the expectation that during the 10 years of data collection, participants would likely progress through the perimenopausal stages. We used an a priori power analysis and determined that a sample size of 2,400 participants would provide 85% power to detect an odds ratio of 1.6 between two comparison groups (such as early vs. late perimenopause) with respect to the individual insomnia symptoms. This calculation was based on the assumption of an overall alpha of .05, twosided test statistic, and 25% missing data. Participants were included if they had complete data for the perimenopausal stage and all insomnia symptom data. The actual percentage of data missing was 5.4%. Data from menopausal women, defined as women who experienced the absence of menses for longer than 1 year, were excluded from analysis because the primary focus of the study was perimenopausal women.
Measures
Insomnia symptoms. The primary dependent variables were self-reported insomnia symptoms measured by the following annual survey items: Over the past 2 weeks, (a) Did you have trouble falling asleep?; (b) Did you wake up several times a night?; (c) Did you wake up earlier than you planned to, and were you unable to fall asleep again?; and (d) Average sleep quality. The first three survey items were rated on a 5-point Likert scale: 1 ¼ no, not in the past 2 weeks; 2 ¼ yes, less than once a week; 3 ¼ yes, 1 or 2 times per week; 4 ¼ yes, 3 to 4 times per week; and 5 ¼ yes, 5 or more times per week. Sleep quality was assessed on a 4-point Likert scale: 1 ¼ restful; 2 ¼ average quality; 3 ¼ restless; and 4 ¼ very restless. These four questions were adapted from the five-item Women's Health Initiative Insomnia Rating Scale from the Women's Health Initiative Project (Troxel et al., 2009 ) by the investigators of the parent study. For the purposes of our analysis, the self-reported sleep disturbances were categorized as follows: Item 1, sleep latency; Item 2, wake after sleep onset; Item 3, early morning awakenings; and Item 4, sleep quality.
The frequency of sleep latency, wake after sleep onset, and early morning awakenings were dichotomized as no (<3 times per week) and yes ($3 times per week), consistent with the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) criteria for insomnia symptoms (American Psychiatric Association, 2013) . Overall, insomnia symptoms were defined as any of the three symptoms being reported as yes. Sleep quality was dichotomized as overall good sleep quality (self-reported ratings of restful or average quality) and overall poor sleep quality (self-reported ratings of restless or very restless). Insomnia disorder is established based on symptoms but also requires daytime impairment assessment; because such data were not collected in the parent study, we report only on insomnia symptoms, not insomnia disorder. Insomnia symptom criteria were defined as any one symptom of prolonged sleep latency, increased wake after sleep onset, and/or the occurrence of early morning awakenings, that was self-reported as present for 3 or more nights per week, for 3 or more consecutive months.
Stage of menopause. Menopause status was defined using the Stages of Reproductive Workshop þ 10 criteria (Harlow et al., 2012) . Irregular menstrual bleeding was used to distinguish between categories of menopause including postmenopausal, late perimenopausal, early perimenopausal, and premenopausal. Postmenopause was defined as no menses for 12 months. Late perimenopause was defined as no menses for the last 3 to 12 months. Early perimenopause was defined as a menses in the last 3 months but menstruation that was not predictable. Premenopause was defined as menses occurring in the last 3 months with no decrease in predictability of menstruation (Harlow et al., 2012) .
Analysis
Descriptive statistics were used to assess the distribution of all study variables (e.g., frequencies, means, and standard deviations) for baseline and annual data. Descriptive analyses with frequencies (n [%]) are reported for each individual symptom for the entire perimenopausal sample, as well as the overall rate of insomnia symptoms. Frequencies were examined by study interval (Year [Y] 0-Y1, Y1-Y2, Y2-Y3, etc.) and across all intervals to describe the overall rate of symptoms of insomnia in perimenopausal women and by perimenopausal stage (early and late).
Repeated measures logistic regression was used to identify if symptoms of insomnia (sleep latency, wake after sleep onset, early morning awakenings, sleep quality) change over time by perimenopausal stage. Changes in self-reported symptoms of insomnia were analyzed annually, from baseline until the participant was considered menopausal, taking into account the menopausal stage (early or late perimenopause). With the identification of any significant difference between stages (p < .05), post hoc analyses were conducted to identify which rates were significantly different. All analyses were conducted with the use of SAS version 9.2. Significance level for this study was identified at p values less than .05 for all analyses.
Results
Sample Description
At baseline, the study sample (N ¼ 3,302) comprised predominantly White (47%), early perimenopausal (45%) and pre-perimenopausal (55%), married (65%) women. Most of the participants completed some college (74%) and were employed outside the home (80% ). Across the 10-year study period, 45% of participants transitioned from pre-perimenopause to early or late perimenopause and 55% transitioned to menopause. With each annual data set evaluated, menopausal women were excluded from the data set, which accounts for a diminishing sample size (see Table 1 ). In Year 10, the early and late perimenopausal groups were similar in size (n ¼ 155 and n ¼ 128, respectively). Additional descriptive characteristics of the participants are displayed in Table 2 . Ciano, C., King, T. S., Wright, R. R., Perlis, M., and Sawyer, A. M.
Incidence of Symptoms of Insomnia
Of the 3,302 women included in this study, 31% (n ¼ 578) at Year 1 and 42% (n ¼ 216) at Year 10 had symptoms of insomnia according to the DSM-5 criteria (American Psychiatric Association, 2013). Additionally, the individual symptoms of insomnia (wake after sleep onset, sleep latency, and early morning awakenings) remained prevalent and steadily increased over the decade of data collection (see Tables 3-5 ).
The symptom most prevalent for perimenopausal women in the study was wake after sleep onset (see Figure 1) . A total of 31% (n ¼ 525) of the early perimenopausal women had insomnia symptoms in Year 1 of the study; the occurrence increased to 39% (n ¼ 60) by Year 10. In the late perimenopausal group, insomnia symptoms were present in 32% (n ¼ 39, Year 1) and 48% (n ¼ 61, Year 10).
Symptom Differences by Perimenopausal Stage
Overall insomnia symptoms were more prevalent in the late stage of perimenopause than the early stage of perimenopause (Figure 1 ). Table 6 Discussion
The purpose of our secondary longitudinal analysis was to describe the prevalence of insomnia symptoms in women during perimenopause and to determine the prevalence of insomnia symptoms in women by perimenopausal stage, early versus late. A major finding of our study was that 31% to 42% of all women in the sample had symptoms of insomnia during perimenopause. In addition, late perimenopausal women had significantly more insomnia symptoms compared with early perimenopausal women. These results suggest that as women transition through the perimenopausal period, a greater incidence of insomnia symptoms is possible.
Insomnia Symptoms During Perimenopause
Based on the study findings, women during perimenopause have exceedingly greater rates of insomnia symptoms than the general North American population, which is estimated at 15% to 20% and, specifically among women Women report a greater prevalence of insomnia symptoms than men; however, the prevalence of insomnia symptoms among women nearly doubles during perimenopause.
Ciano, C., King, T. S., Wright, R. R., Perlis, M., and Sawyer, A. M. across the life span, to average 16% (Morin et al., 2011b) . This finding suggests a greater likelihood of insomnia symptoms during perimenopause.
At any time across the 10-year study period, at least 18% (n ¼ 280) of perimenopausal women categorized their sleep quality as poor. However, wake after sleep onset and early morning awakenings increased over the study period as perimenopausal women progressed through perimenopause, whereas difficulty falling asleep was not as frequently reported. This could indicate that the single insomnia symptom of difficulty falling asleep is closely associated with sleep quality but that other insomnia symptoms are not recognized by perimenopausal women as insomnia specific.
Perimenopausal women may not recognize their insomnia symptoms as indicators of a sleep disorder, such as insomnia disorder. Perimenopausal women may accept sleep disturbances as normal and therefore may be unlikely to seek treatment (Nosek et al., 2012) . In a Gallup poll conducted in the United States, it was reported that only 5% of insomniacs ever seek treatment from a health care professional (Ancoli-Israel & Roth, 1999) . By delaying or not seeking treatment of insomnia symptoms, the likelihood of chronic insomnia increases (Ohayon, 2006) . This is likely the result of behavioral changes such as napping, sleeping in late on weekends or going to bed early, and rumination about sleep, which perpetuate the cycle of insomnia (Perlis et al., 2011) .
Insomnia Prevalence by Perimenopausal Stages
In prior published studies, researchers found that approximately half of all perimenopausal women experienced sleep disturbances (Kravitz et al., 2003; National Sleep Foundation, 2007; 2. In the last 2 weeks did you wake up several times a night?
3. In the last 2 weeks have you woken up earlier than planned to and were not able to go back to sleep again? For any reported symptom in our sample, women in the late perimenopausal stage had a greater frequency of self-reported insomnia symptoms than early perimenopausal women. As women progressed from early to late perimenopause, the adjusted odds of poor sleep quality were 1.3 times those in early perimenopause. These findings extend and support the work of Kravitz et al. (2008) , who reported that sleep disturbances are associated with perimenopause and are more prevalent in the late perimenopausal stage (Kravitz and Joffe, 2011) . This is not unique to the United States. In Australia, researchers reported that sleep problems increased as women progressed from the late reproductive to early menopausal years in a 9-year longitudinal study; however, this was measured by asking participants about trouble sleeping, which is not a measurable insomnia symptom (Dennerstein et al., 2007) . Woods and Mitchell (2010) reported that nighttime awakenings worsened in the late perimenopause to postmenopausal stages, which further supported our findings.
The transition from early to late perimenopause is therefore likely to be a major precipitating factor in the development of insomnia disorder, as indicated by the greater prevalence of insomnia symptoms that emerge during perimenopause. This precipitating factor is associated with fluctuations in estradiol, follicle-stimulating hormone, and inhibin B, all measures of ovarian aging (Freedman, 2005b; Freeman et al., 2007) . Hot flashes triggered by slight increases in core body temperature, a reduced thermoneutral zone in the brain, and fluctuations in endogenous hormones as women transition to late perimenopause influence the development of insomnia disorder in perimenopausal women (Freedman, 2005a,b) . Because perimenopause and, in particular, late perimenopause are caused by biophysiologic changes that also influence sleep regulation and sleep continuity, perimenopausal women should be considered a high-risk group for insomnia disorders.
Implications
Through our findings we suggest that assessment of sleep in perimenopausal women is clinically necessary. It is important for nurses, primary care providers, and women's health providers to initiate screenings for insomnia symptoms in this high-risk population. Nurses are in an opportune position to initiate screenings regarding sleep and educate women on simple changes to improve their sleep patterns. During routine health visits, questions related to insomnia symptoms and sleep satisfaction should be used. Screenings should at a minimum consist of the four sleep questions used in the SWAN study (see Table 7 ); alternatively, validated insomnia instruments such as the Insomnia Severity Index (Morin et al., 2011a) or the Pittsburgh Sleep Quality Index (Morin et al., 2011a) could be used to identify perimenopausal women at risk for insomnia disorder. Such an approach will support the much-needed conversations among providers and midlife women about the risk and negative health outcomes associated with insomnia disorder.
Insomnia disorder has a negative effect on health outcomes, confers cardiometabolic consequences, and increases the risk of depression and hypertension (Joffe et al., 2010; Matthews et al., 2014; Serrano and Warnock, 2007) . Grandner et al. (2012) reported a significant risk for obesity, diabetes, myocardial infarction, and coronary artery disease among adults who reported insomnia disorder. Health care-related costs associated with insomnia disorder are estimated at $15 billion annually (Daley et al., 2009) . Based on our findings that perimenopausal women have a greater prevalence of insomnia symptoms, which may be indicative of insomnia disorder or may be predisposing factors for the development of insomnia disorder, it is imperative to recognize insomnia symptoms among middle-aged women by conducting regular insomnia risk screening. In addition, practitioners and researchers in the fields of women's health and sleep need to prioritize insomnia disorder as a potentially underrecognized and underdiagnosed sleep disorder in perimenopausal women.
Limitations
According to the DSM-5, a diagnosis of insomnia disorder must include nighttime and daytime impairment in the presence of ample opportunity for sleep to occur (American Psychiatric Association, 2013) . A limitation of our study was the absence of SWAN data to permit examination
The transition from early to late perimenopause may be a major precipitating factor in the development of symptoms of insomnia.
Ciano, C., King, T. S., Wright, R. R., Perlis, M., and Sawyer, A. M.
of daytime impairment; therefore, identification of diagnosable insomnia disorder among the participants was not possible. Our study results, however, suggested that perimenopausal women do experience insomnia symptoms, which may indicate a greater prevalence of insomnia disorder. An additional limitation was that sleep-wake disorders such as obstructive sleep apnea, restless leg syndrome, and circadian sleep-wake disorders, as well as the use of sleep aids, were not accounted for because of the absence of these data in the SWAN data set. This is an important limitation to note, because other sleep-wake disorders and use of sleep aids (pharmacologic and nonpharmacologic) are potential extraneous variables. Additionally, our results were not adjusted for age, which could be a confounder for agerelated sleep changes (Dijk et al., 2000) .
Our study was based on self-reported sleep data, a commonly used method in sleep research. However, the use of subjective and objective sleep data would further strengthen study results by permitting validation of subjective sleep data. The use of sleep diaries in studies of this phenomenon will potentially provide insights into patterns of sleep in perimenopausal women; risk of recall bias, a limitation in our study, is reduced by the inclusion of such a measure. The use of actigraphy, or accelerometry, in addition to the subjective sleep measures, would also strengthen subsequent studies.
Finally, the secondary analysis design of our study did not permit for the control of all confounding factors, such as sedentary lifestyle, obesity, normal aging, and use of sleep medications. Future researchers who focus on the phenomenon of insomnia in perimenopausal women may consider a more complete and robust sleep data collection approach to validate the findings of the current study and extend knowledge about this phenomenon.
Recommendations for Research
To date, it is unclear why perimenopausal women are predisposed to insomnia symptoms. It is hypothesized that fluctuations in hormone levels as the ovaries age precipitate vasomotor symptoms that contribute to sleep disturbances and self-reported insomnia symptoms. Future investigators of insomnia symptoms in perimenopausal women should include physiologic measures, such as estradiol, follicle-stimulating hormone, and inhibin B, and objective measures of sleep, such as polysomnography and actigraphy. These are important methodologic considerations to better understand the trajectory of hormonal and sleep changes during the transition to menopause.
Conclusion
Understanding the prevalence of insomnia symptoms in perimenopausal women is a critical consideration given the 500 million women who will be entering perimenopause in the next decade (U.S. Census Bureau, 2010) and the negative health outcomes associated with insomnia disorder (Grandner et al., 2012; Matthews et al., 2014; Terauchi et al., 2012) . During perimenopause, women experience greater rates of insomnia symptoms than the rates reported for the general adult population, and insomnia symptoms are increasingly frequent in late perimenopause compared with early perimenopause. Screening for insomnia symptoms by health care providers is necessary to identify perimenopausal women at risk for insomnia disorder, which may reduce the burden of insomnia disorder among women during perimenopause. Intervention research is warranted to improve sleep and long-term health outcomes in perimenopausal women.
